Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Common Equity: 2015-2024

Historic Common Equity for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $134.3 million.

  • Editas Medicine's Common Equity fell 92.34% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 92.34%. This contributed to the annual value of $134.3 million for FY2024, which is 61.54% down from last year.
  • Latest data reveals that Editas Medicine reported Common Equity of $134.3 million as of FY2024, which was down 61.54% from $349.1 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Common Equity peaked at $553.6 million during FY2021, and registered a low of $134.3 million during FY2024.
  • For the 3-year period, Editas Medicine's Common Equity averaged around $281.4 million, with its median value being $349.1 million (2023).
  • In the last 5 years, Editas Medicine's Common Equity spiked by 49.97% in 2020 and then crashed by 61.54% in 2024.
  • Editas Medicine's Common Equity (Yearly) stood at $393.6 million in 2020, then skyrocketed by 40.67% to $553.6 million in 2021, then slumped by 34.85% to $360.7 million in 2022, then decreased by 3.21% to $349.1 million in 2023, then plummeted by 61.54% to $134.3 million in 2024.